TP53, NOTCH1, MYC, and BIRC3 have been observed with greater frequency in RT than in typical CLL progression, suggesting that these alterations may drive the aggressive phenotype and influence poor patient prognosis [6,12]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.